- Home
- AWH vs APLM Comparison
AWH vs APLM Comparison
Compare AWH & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AWH
- APLM
- Stock Information
- Founded
- AWH 1993
- APLM 2016
- Country
- AWH United States
- APLM United States
- Employees
- AWH N/A
- APLM N/A
- Industry
- AWH Medical/Dental Instruments
- APLM Blank Checks
- Sector
- AWH Health Care
- APLM Finance
- Exchange
- AWH Nasdaq
- APLM Nasdaq
- Market Cap
- AWH 13.5M
- APLM 15.6M
- IPO Year
- AWH N/A
- APLM N/A
- Fundamental
- Price
- AWH $0.75
- APLM $0.10
- Analyst Decision
- AWH Buy
- APLM Strong Buy
- Analyst Count
- AWH 2
- APLM 2
- Target Price
- AWH $4.40
- APLM $4.25
- AVG Volume (30 Days)
- AWH 139.7K
- APLM 1.2M
- Earning Date
- AWH 11-14-2024
- APLM 08-14-2024
- Dividend Yield
- AWH N/A
- APLM N/A
- EPS Growth
- AWH N/A
- APLM N/A
- EPS
- AWH N/A
- APLM N/A
- Revenue
- AWH $8,923,000.00
- APLM $2,101,000.00
- Revenue This Year
- AWH $15.56
- APLM N/A
- Revenue Next Year
- AWH $105.32
- APLM N/A
- P/E Ratio
- AWH N/A
- APLM N/A
- Revenue Growth
- AWH N/A
- APLM 70.54
- 52 Week Low
- AWH $0.72
- APLM $0.08
- 52 Week High
- AWH $5.65
- APLM $1.23
- Technical
- Relative Strength Index (RSI)
- AWH 33.23
- APLM 30.56
- Support Level
- AWH $0.84
- APLM $0.11
- Resistance Level
- AWH $0.87
- APLM $0.13
- Average True Range (ATR)
- AWH 0.09
- APLM 0.01
- MACD
- AWH -0.02
- APLM -0.00
- Stochastic Oscillator
- AWH 12.87
- APLM 22.27
About AWH Aspira Women's Health Inc.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.